Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Nutr Health ; 23(4): 271-279, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29214925

RESUMO

BACKGROUND: Exercise and supplementation with isoflavones are therapies used to prevent and treat climacteric symptoms. AIM: To verify the effects of 10 weeks of combined aerobic and resistance training and isoflavone supplementation on climacteric symptoms in postmenopausal women. METHODS: A randomised, double-blind, controlled clinical trial was performed. A total of 32 postmenopausal women, aged 54.4 ± 5.4 years, with a body mass index of 26.6 ± 3.0 kg/m2 and 5.6 ± 4.6 years after menopause, were randomly assigned to groups: placebo and exercise (PLA + EXE, n = 15) or 100 mg of isoflavone and exercise (ISO + EXE, n = 17). At the beginning and after 10 weeks of aerobic + resistance (20 min each, moderate intensity) training, climacteric symptoms were evaluated using the Blatt-Kupperman Menopausal Index, Cervantes Scale and Menopause Rating Scale. ANCOVA was used for analysis between groups and at different times, with the covariate adjusted by the pre-value. The level of significance considered was p < 0.05. RESULTS: A reduction in climacteric symptoms was observed in both groups, without differences between the interventions. The reductions were 45% and 50% for the Blatt-Kupperman Menopausal Index, 41% and 52% for the MRS and 39% and 39% for the Cervantes Scale in the ISO + EXE and PLA + EXE groups, respectively. In the descriptive analysis of the Blatt-Kupperman Menopausal Index values, there was an increase in the absence of symptoms from 48-77% in the ISO + EXE group and 24-58% in the PLA + EXE group. CONCLUSIONS: A period of 10 weeks of combined training was effective in improving climacteric symptoms in post-menopausal women. However, isoflavone supplementation did not promote additional effects in improving symptoms.


Assuntos
Climatério , Transtorno Depressivo/prevenção & controle , Exercício Físico , Qualidade de Vida , Treinamento Resistido , Distúrbios do Início e da Manutenção do Sono/prevenção & controle , Vertigem/prevenção & controle , Brasil , Climatério/psicologia , Terapia Combinada , Transtorno Depressivo/etiologia , Transtorno Depressivo/fisiopatologia , Transtorno Depressivo/psicologia , Suplementos Nutricionais , Método Duplo-Cego , Exercício Físico/psicologia , Feminino , Seguimentos , Humanos , Isoflavonas/uso terapêutico , Pessoa de Meia-Idade , Fitoestrógenos/uso terapêutico , Pós-Menopausa , Autorrelato , Índice de Gravidade de Doença , Distúrbios do Início e da Manutenção do Sono/etiologia , Distúrbios do Início e da Manutenção do Sono/fisiopatologia , Distúrbios do Início e da Manutenção do Sono/psicologia , Vertigem/etiologia , Vertigem/fisiopatologia , Vertigem/psicologia
2.
Otol Neurotol ; 26(5): 1022-6, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16151353

RESUMO

OBJECTIVE: To establish whether the oral administration of moderate doses of prednisone reduces refractory vertigo in Ménière's disease. STUDY DESIGN: Blinded, randomized, controlled trial. SETTING: Tertiary referral center. PATIENTS: Patients with Ménière's disease with limited vertigo control (Class C) and severe disability (Scale 3). INTERVENTIONS: Two groups (n = 8 per group) were treated orally with either diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h) (control group), or the same treatment plus prednisone (0.35 mg/kg) daily for 18 weeks (prednisone group). MAIN OUTCOME MEASURES: The variables evaluated were the frequency and duration of vertigo, tinnitus, aural fullness, and audiographic parameters. The clinical surveillance was performed for 12 months after prednisone withdrawal. RESULTS: The frequency and duration of vertigo episodes were reduced by 50% and 30%, respectively, by prednisone treatment. Prednisone-treated patients manifested a significant reduction in tinnitus. No changes were observed in aural fullness or hearing. No metabolic or infectious disorders were observed. CONCLUSION: Oral prednisone helps to control refractory vertigo in Ménière's disease. These preliminary data suggest that prednisone can be a good noninvasive antivertigo management regimen for these patients.


Assuntos
Glucocorticoides/uso terapêutico , Doença de Meniere/tratamento farmacológico , Prednisona/uso terapêutico , Vertigem/prevenção & controle , Administração Oral , Adulto , Feminino , Glucocorticoides/administração & dosagem , Humanos , Masculino , Doença de Meniere/complicações , Pessoa de Meia-Idade , Projetos Piloto , Prednisona/administração & dosagem , Zumbido/etiologia , Zumbido/prevenção & controle , Resultado do Tratamento , Vertigem/etiologia
3.
Iatreia ; Iatreia;1(2): 108-113, dic. 1988. ilus
Artigo em Espanhol | LILACS | ID: lil-82334

RESUMO

Se presenta una clasificacion del vertigo segun su localizacion antomica. su duracion y sus caracteristicas clinicas; se hace un resumen de las drogas ototxicas de uso frecuente y de las que, sin serlo, pueden producir mareo; se discuten diversos aspectos del manejo de esta entidad y se propone un tratamiento racional enfocado sobre cinco aspectos principales, a saber: preventivo, de rehabilitacion, psicoterapeutico, farmacologico y quirurgico


A classification of vertigo according to its anatomy collocation, duration and clinical characteristics is presented along with a summary of the most frequently employed ototoxic drugs and of those that, not being ototoxic, can produce dizziness. We discuss different aspects concerning the management of this entity. specially those within the scope of the general.


Assuntos
Humanos , Masculino , Feminino , Vertigem , Vertigem/cirurgia , Vertigem/classificação , Vertigem/diagnóstico , Vertigem/prevenção & controle , Vertigem/tratamento farmacológico , Vertigem/reabilitação , Vertigem/terapia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA